By Matthew Bultman (July 30, 2019, 7:46 PM EDT) -- The full Federal Circuit said Tuesday it would not reconsider a May ruling that invalidated two patents on Horizon Pharma's pain reliever Vimovo, leaving in place a decision the drugmaker argued upended years of the court's own precedent.
The court denied a request for an en banc rehearing brought by Horizon Pharma Inc. and its partner, Nuvo Pharmaceuticals Inc., after a three-judge panel found the patents failed to satisfy written description requirements. The companies said the ruling will harm innovation and "imperils numerous patents."
"We are disappointed by the court of appeals' decision today, but remain undeterred in our efforts to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!